Specimen:
Collect
- One Lavender (EDTA)
Also Acceptable:
- One Pink Top (EDTA)
Submit
- 4 mL (Min:2 mL) Whole blood in Lavender (EDTA). Submit Refrigerated.
Also Acceptable:
- 4 mL (Min:2 mL) Whole blood in Pink Top (EDTA). Submit Refrigerated.
Special Handling
- Variant analyzed: c.*97G>A, previously referred to as G20210A.
Rejection Criteria
- Shared samples - a separate sample must be collected for molecular testing (Testing for MTHFR, FACTOR V, and PT GENE MUTATION may be performed from same tube).
Stability
Ambient: Unacceptable; Refrigerated: 1 Month(s); Frozen: Unacceptable; Incubated: Unacceptable
Methodology
- Mass Spectrometry Coupled with End-Point PCR
Performed
Wednesday
Reported
1-7 Day(s)
CPT Codes
- 81240
Interpretive Data
General Reference Range : negative
Where appropriate, medical consultation and/or genetic counseling should be offered to patients to inform and explain the risk implications and genetic implications of these test results.
Patient DNA is assayed for the Prothrombin G20210A mutation by polymerase chain reaction (PCR) and MOLDI-TOF mass spectrometry technology. The product of PCR is detected on the Agena Bioscience MassARRAY system.
The expression of Factor II thrombophilia is impacted by coexisting genetic thrombophilic disorders, acquired thrombophilic disorders (eg, malignancy, hyperhomocysteinemia, high factor VIII levels), and circumstances including: pregnancy, oral contraceptive use, hormone replacement therapy, selective estrogen receptor modulators, travel, central venous catheters, surgery, and organ transplantation. The test result must be interpreted along with the patient's clinical history and other pertinent laboratory data.
Variant analyzed: c.97G>A (G20210A), previously referred to as Factor II Gene Mutation.
Laboratory Developed Test (LDT). This test was developed and its performance characteristics determined by Interpath Laboratory in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.
Where appropriate, medical consultation and/or genetic counseling should be offered to patients to inform and explain the risk implications and genetic implications of these test results.
Patient DNA is assayed for the Prothrombin G20210A mutation by polymerase chain reaction (PCR) and MOLDI-TOF mass spectrometry technology. The product of PCR is detected on the Agena Bioscience MassARRAY system.
The expression of Factor II thrombophilia is impacted by coexisting genetic thrombophilic disorders, acquired thrombophilic disorders (eg, malignancy, hyperhomocysteinemia, high factor VIII levels), and circumstances including: pregnancy, oral contraceptive use, hormone replacement therapy, selective estrogen receptor modulators, travel, central venous catheters, surgery, and organ transplantation. The test result must be interpreted along with the patient's clinical history and other pertinent laboratory data.
Variant analyzed: c.97G>A (G20210A), previously referred to as Factor II Gene Mutation.
Laboratory Developed Test (LDT). This test was developed and its performance characteristics determined by Interpath Laboratory in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.
Components
- 1153 - PT GENE MUTATION
Last Updated: May 19, 2025 @ 9:13 am
Disclaimer:
It is preferable to locate tests on the website and not rely on printed test information, which may soon be out of date. Updated test information can only be guaranteed by using this website.
